CO2023007904A2 - Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma - Google Patents

Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma

Info

Publication number
CO2023007904A2
CO2023007904A2 CONC2023/0007904A CO2023007904A CO2023007904A2 CO 2023007904 A2 CO2023007904 A2 CO 2023007904A2 CO 2023007904 A CO2023007904 A CO 2023007904A CO 2023007904 A2 CO2023007904 A2 CO 2023007904A2
Authority
CO
Colombia
Prior art keywords
dry powder
powder formulation
asthma
lipocalin mutein
treatment
Prior art date
Application number
CONC2023/0007904A
Other languages
English (en)
Inventor
Mary Fitzgerald
David Robert Close
Philip Gardiner
Robert Alexander Palmér
Marja Riikka Savolainen
Sandra Gracin
Ankur Ajmera
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CO2023007904A2 publication Critical patent/CO2023007904A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención está relacionada con el tratamiento del asma en un sujeto humano mediante la administración por inhalación oral de una formulación de polvo seco que comprende una cantidad con eficacia terapéutica de una muteína de lipocalina contra el receptor alfa de IL-4 (IL-4Rα), o una variante o fragmento de esta, a dicho sujeto. La invención también está relacionada con la formulación de polvo seco que comprende la muteína de lipocalina contra el receptor alfa de IL-4 (IL-4Rα), o una variante o un fragmento de esta.
CONC2023/0007904A 2020-12-18 2023-06-16 Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma CO2023007904A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063127903P 2020-12-18 2020-12-18
PCT/EP2021/086730 WO2022129629A1 (en) 2020-12-18 2021-12-20 Lipocalin mutein dry powder formulation for treatment of asthma

Publications (1)

Publication Number Publication Date
CO2023007904A2 true CO2023007904A2 (es) 2023-10-30

Family

ID=79686778

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0007904A CO2023007904A2 (es) 2020-12-18 2023-06-16 Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma

Country Status (15)

Country Link
EP (1) EP4262845A1 (es)
JP (1) JP2023553703A (es)
KR (1) KR20230121785A (es)
CN (1) CN116916945A (es)
AR (1) AR124436A1 (es)
AU (1) AU2021399151A1 (es)
CA (1) CA3199479A1 (es)
CL (1) CL2023001775A1 (es)
CO (1) CO2023007904A2 (es)
CR (1) CR20230265A (es)
IL (1) IL303729A (es)
MX (1) MX2023007174A (es)
PE (1) PE20240799A1 (es)
TW (1) TW202241490A (es)
WO (1) WO2022129629A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
WO2008015239A2 (en) 2006-08-01 2008-02-07 Pieris Ag Muteins of tear lipocalin and methods for obtaining the same
CN105949301B (zh) 2010-06-08 2020-03-27 皮里斯制药有限公司 结合IL-4受体α的泪脂质运载蛋白突变蛋白
CA2858962C (en) 2011-12-13 2023-09-05 Pieris Ag Compositions of human tear lipocalin muteins and methods of use thereof
EP3946417A1 (en) * 2019-03-29 2022-02-09 Pieris Pharmaceuticals GmbH Inhaled administration of lipocalin muteins
WO2020200960A1 (en) 2019-03-29 2020-10-08 Astrazeneca Ab Lipocalin mutein for treatment of asthma

Also Published As

Publication number Publication date
IL303729A (en) 2023-08-01
CN116916945A (zh) 2023-10-20
KR20230121785A (ko) 2023-08-21
MX2023007174A (es) 2023-09-08
AR124436A1 (es) 2023-03-29
CL2023001775A1 (es) 2024-01-19
EP4262845A1 (en) 2023-10-25
JP2023553703A (ja) 2023-12-25
PE20240799A1 (es) 2024-04-18
TW202241490A (zh) 2022-11-01
WO2022129629A1 (en) 2022-06-23
CR20230265A (es) 2023-09-29
AU2021399151A1 (en) 2023-07-27
CA3199479A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
ECSP21051833A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
CL2019003924A1 (es) Uso de pridopidina para el tratamiento de la disminución funcional. (divisional solicitud 201900485).
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
ECSP099556A (es) Nuevos métodos
BR112016018008A2 (pt) Implante de osso
CL2010000434A1 (es) Uso de una composicion farmaceutica que comprende vitamina b12 y acido n-(8-(2-hidroxibenzoil)animo) caprilico o sus sales para preparar un medicamento util en el tratamiento de la deficiencia de vitamina b12; composicion farmaceutica.
AR077573A2 (es) Uso de un inhibidor de tnf y composicion farmaceutica que lo comprende
SV2008002855A (es) Milnacipran para el tratamiento a largo plazo del sindrome de fibromialgia
CL2011003003A1 (es) Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria.
AR072805A1 (es) Composiciones intranasales formas galenicas y metodos de tratamiento.
TR201908938T4 (tr) Ağız, boğaz ve solunum yolu rahatsızlıklarının tedavisi için formülasyonlar.
PA8784901A1 (es) Utilizacion de un antagonista par1 en el tratamiento de la fibrilacion atrial
PE20211489A1 (es) Formas de dosificacion pediatricas de vitamina d, metodos de elaboracion y uso
CO2020013427A2 (es) Formulaciones de ciclosporina para uso en el tratamiento del síndrome de bronquiolitis obliterante (bos)
DOP2017000055A (es) Tratamientos médicos a base de anamorelina
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
CO2021000450A2 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
CO2023007904A2 (es) Formulación de polvo seco de muteína de lipocalina para el tratamiento del asma
CO2022008001A2 (es) Métodos para el tratamiento de trastornos depresivos
EA200801824A1 (ru) Лечебно-профилактический состав для ухода за полостью рта
UY31097A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante
BR112018010497A8 (pt) combinação sinérgica de ácido pirrolidona-carboxílico e/ou seus sais e de ácido hialurônico e/ou seus sais para utilização no tratamento e/ou prevenção de secura e irritação da mucosa e suas formulações farmaceuticas relacionadas
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
BR112023003536A2 (pt) Composições para tratamento bucal que compreendem flavonoides prenilados
BR112012007399A2 (pt) composição de cuidado oral, usos da interleucina-1 recombinante humana e métodos para reduzir o mau hálito e para o tratamento ou prevenção de doença periodontal.